The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Patients with diabetes are at higher risk for death and cardiovascular outcomes than the general population. We investigated whether the excess risk of death and cardiovascular events among patients with type 2 diabetes could be reduced or eliminated. METHODS: In a cohort study, we included 271,174 patients with type 2 diabetes who were registered in the Swedish National Diabetes Register and matched them with 1,355,870 controls on the basis of age, sex, and county. We assessed patients with diabetes according to age categories and according to the presence of five risk factors (elevated glycated hemoglobin level, elevated low-density lipoprotein cholesterol level, albuminuria, smoking, and elevated blood pressure). Cox regression was used to study the excess risk of outcomes (death, acute myocardial infarction, stroke, and hospitalization for heart failure) associated with smoking and the number of variables outside target ranges. We also examined the relationship between various risk factors and cardiovascular outcomes. RESULTS: The median follow-up among all the study participants was 5.7 years, during which 175,345 deaths occurred. Among patients with type 2 diabetes, the excess risk of outcomes decreased stepwise for each risk-factor variable within the target range. Among patients with diabetes who had all five variables within target ranges, the hazard ratio for death from any cause, as compared with controls, was 1.06 (95% confidence interval [CI], 1.00 to 1.12), the hazard ratio for acute myocardial infarction was 0.84 (95% CI, 0.75 to 0.93), and the hazard ratio for stroke was 0.95 (95% CI, 0.84 to 1.07). The risk of hospitalization for heart failure was consistently higher among patients with diabetes than among controls (hazard ratio, 1.45; 95% CI, 1.34 to 1.57). In patients with type 2 diabetes, a glycated hemoglobin level outside the target range was the strongest predictor of stroke and acute myocardial infarction; smoking was the strongest predictor of death. CONCLUSIONS: Patients with type 2 diabetes who had five risk-factor variables within the target ranges appeared to have little or no excess risk of death, myocardial infarction, or stroke, as compared with the general population. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“when all major cardiovascular risk factors are treated to within the target ranges, people with type 2 diabetes have risk of death, MI, or stroke similar to that of the general population (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among persons with type 2 diabetes (T2D), cardiovascular risk and mortality are dependent on the number of uncontrolled risk factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the evidence from prospective intervention studies to support comprehensive ASCVD risk factor reduction, a large cohort study confirmed no or only marginally increased mortality, MI, and stroke risk compared with the general population when all major cardiovascular risk factors are managed to goal levels in people with type 2 diabetes (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hypertriglyceridemia is indirectly linked with changes in HDL-C and LDL-C composition that are conducive to accelerated atherogenesis.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In persons with fasting triglycerides of 200 to 499 mg/dL, despite tight adherence to a healthy diet (to include reduced intake of simple carbohydrates and avoidance of fruit juices and alcohol) and optimized glycemia control, prescribe statin therapy to the maximum tolerated dose to achieve goals for non-HDL-C or apo B, since all apo B–containing particles are potentially atherogenic.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“To date, aside from icosapent ethyl, fish oil therapy has not been shown to prevent CV adverse events.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“No RCT has yet been reported to investigate the benefit of reducing severe (>500 mg/dL) or moderate (>200 mg/dL) hypertriglyceridemia to prevent CVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite these newer therapies, the risk of kidney failure remains high, particularly in those whose risk factors are insufficiently controlled.6,7”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“In patients with advanced disease, e.g.T2DM and established microalbuminuria, an intensive, target-driven, multifactorial therapy (Steno-2 study; targets: HbA1c <6.5%, total cholesterol <4.5 mmol/L [175 mg/dL], and BP <130/80 mmHg) resulted in 50% fewer microvascular and macrovascular events after 7.8 years of follow-up.361”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [361]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citation
Cited by
Sorted by citations
Items 501–600 of 999
Yandrapalli, S., Jolly, G. P., Horblitt, A. M., Pemmasani, G., Sanaani, A., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000308 · Cited by 12
Eliasson, B., Ericsson, Å., Fridhammar, A., Nilsson, A., Persson, S., & Chubb, B. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00317-z · Cited by 14
Self-citationChowdhary, A., Thirunavukarasu, S., Jex, N., Coles, L., Bowers, C., Sengupta, A., Swoboda, P., Witte, K., Cubbon, R., Xue, H., et al. (2022) · Obesity · doi:10.1002/oby.23413 · Cited by 10
Majchrzak, C., Cougnard‐Grégoire, A., Goff, M. L., Féart, C., Delcourt, C., Prezelin‐Reydit, M., Helmer, C., & Rigalleau, V. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.08.009 · Cited by 12
Evaluating gliclazide for the treatment of type 2 diabetes mellitus
Tomlinson, B., Li, Y.-H., & Chan, P. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2141108 · Cited by 14
Self‐care in migrants with type 2 diabetes, during the COVID ‐19 pandemic
Pettersson, S., Jaarsma, T., Hedgard, K., & Klompstra, L. V. (2022) · Journal of Nursing Scholarship · doi:10.1111/jnu.12842 · Cited by 12
Cardoso, H., Bello, C., Andrade, L., do Rosário, F. S., Louro, J., Nogueira, C., Rodrigues, E., Vieira, N., & Carqueja, T. (2023) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2022.04.011 · Cited by 13
Patoulias, D., Stavropoulos, K., Imprialos, K. P., Athyros, V. G., Doumas, M. N., & Karagiannis, A. I. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190426162746 · Cited by 13
Bakke, Å., Dalen, I., Thue, G., Cooper, J. G., Skeie, S., Berg, T. J., Jenum, A. K., Claudi, T., Løvaas, K. F., & Sandberg, S. (2019) · Diabetic Medicine · doi:10.1111/dme.14159 · Cited by 14
Höskuldsdóttir, G., Franzén, S., Eeg‐Olofsson, K., & Eliasson, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-16135-0 · Cited by 14
Self-citationCommentary: Glucose control: Not just a bystander in GLP-1RA-mediated cardiovascular protection
Caruso, I., Cignarelli, A., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154272 · Cited by 11
Lac-Phe induces hypophagia by inhibiting AgRP neurons in mice
Liu, H., Li, V. L., Liu, Q., Liu, Y., Su, C., Wong, H.-X. K., Yin, N., Liu, H., Fang, X., McDermott, K. M., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01377-9 · Cited by 11
Başaran, Ö. (2023) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2022.2012 · Cited by 11
Xue, Q., Li, X., Wang, X., Ma, H., Heianza, Y., & Qi, L. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.01.024 · Cited by 11
Niu, S., Alkhuzam, K. A., Guan, D., Jiao, T., Shi, L., Fonseca, V. A., Laiteerapong, N., Ali, M. K., Schatz, D., Guo, J. S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15332 · Cited by 11
Avdic, T., Carlsen, H. K., Isaksson, R., Guðbjörnsdóttir, S., Mandalenakis, Z., Franzén, S., Sattar, N. A., Beckman, J. A., McGuire, D. K., & Eliasson, B. (2023) · Diabetes Care · doi:10.2337/dc23-1198 · Cited by 11
Self-citationDenimal, D., Duvillard, L., Béland‐Bonenfant, S., Terriat, B., de Barros, J.-P. P., Simoneau, I., Rouland, A., Houbachi, L., Bouillet, B., Vergès, B. L., et al. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101542 · Cited by 11
Cases, A., Broseta, J. J., Marqués, M., Guldris, S. C., Mauro, J. C. J., Arroyo, R. A., & Ortíz, A. (2024) · Nefrología · doi:10.1016/j.nefro.2024.05.001 · Cited by 14
Impacto de la obesidad y la diabetes en la salud y en la enfermedad cardiovascular
Lecube, A. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103045 · Cited by 11
Minutolo, R., Simeon, V., Nicola, L. D., Chiodini, P., Galiero, R., Rinaldi, L., Caturano, A., Vetrano, E., Sardu, C., Marfella, R., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02371-3 · Cited by 12
Li, B., Yang, Z., Liu, Y., Zhou, X. J., Wang, W., Gao, Z., Yan, L., Qin, G.-J., Tang, X., Wan, Q., et al. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13596 · Cited by 12
Cardiometabolic medicine: time to recognize a new clinical specialty?
Krentz, A. J., & Jacob, S. (2019) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000173 · Cited by 11
Johansson, I., & Norhammar, A. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108822 · Cited by 11
Борисовна, Л. Е., Васильева, А. А., Karelkina, E. V., Boyarinova, M. A., Mikhaylov, E. N., Рыжков, А. В., Babenko, A. Y., Конради, А. О., & Моисеева, О. М. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102843 · Cited by 11
Stevens, S. R., Segar, M. W., Pandey, A., Lokhnygina, Y. V., Green, J. B., McGuire, D. K., Standl, E., Peterson, E. D., & Holman, R. R. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01603-8 · Cited by 11
Self-citationDistribution of lean mass and mortality risk in patients with type 2 diabetes
Ding, L., Fan, Y., Qiao, J., He, J., Wang, R., He, Q., Cui, J., Ma, Z., Zheng, F., Gao, H., et al. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.09.003 · Cited by 11
Gulsin, G. S., Τζίμας, Γ., Holmes, K.-R., Takagi, H., Sellers, S., Blanke, P., Koweek, L., Nørgaard, B. L., Jensen, J., Rabbat, M., et al. (2023) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.220276 · Cited by 11
Zarrouk, M., Franzén, S., Acosta, S., Nilsson, P. M., Miftaraj, M., Eliasson, B., Svensson, A., & Gottsäter, A. (2019) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2019.01.011 · Cited by 11
Self-citationTancredi, M., Rosengren, A., Svensson, A., Pivodic, A., Guðbjörnsdóttir, S., Wedel, H., & Lind, M. (2019) · Open Heart · doi:10.1136/openhrt-2018-000967 · Cited by 11
Self-citationLatest Evidence on Sulfonylureas: What’s New?
Leiter, L. A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00812-2 · Cited by 12
Andersson, T., Pikkemaat, M., Schiöler, L., Hjerpe, P., Carlsson, A. C., Wändell, P. E., Manhem, K., Kahan, T., Hasselström, J., & Boström, K. B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237107 · Cited by 11
Kjellberg, J., Tikkanen, C. K., Bagger, M., & Gæde, P. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1837626 · Cited by 11
Espinoza, L., Fedorchak, S., & Boychuk, C. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.624595 · Cited by 11
Potential Alteration of Statin‐Related Pharmacological Features in Diabetes Mellitus
Mashayekhi‐Sardoo, H., Atkin, S. L., Montecucco, F., & Sahebkar, A. (2021) · BioMed Research International · doi:10.1155/2021/6698743 · Cited by 11
Just, K. S., Tittel, S. R., Bollheimer, C., Naudorf, M., Laubner, K., Zimny, S., Zeyfang, A., Hummel, M., Stingl, J., & Holl, R. W. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.05.006 · Cited by 11
Scarale, M. G., Antonucci, A., Cardellini, M., Copetti, M., Salvemini, L., Menghini, R., Mazza, T., Casagrande, V., Ferrazza, G., Lamacchia, O., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab472 · Cited by 11
Kafeel, S., Hashim, Z., Fawwad, A., & Nawab, S. N. (2022) · Acta Diabetologica · doi:10.1007/s00592-021-01832-5 · Cited by 11
Lee, I., Kim, J., & Kang, H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19010510 · Cited by 11
Jeong, S., Cho, S., & Kong, S. Y. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00882-1 · Cited by 11
Severe COVID-19 Infection in Type 1 and Type 2 Diabetes During the First Three Waves in Sweden
Edqvist, J., Lundberg, C. E., Andréasson, K., Bjorck, L. M., Dikaiou, P., Ludvigsson, J., Lind, M., Adiels, M., & Rosengren, A. (2023) · Diabetes Care · doi:10.2337/dc22-1760 · Cited by 11
Self-citationYe, N., Yang, L., Wang, G., Bian, W., Xu, F., Ma, C., Zhao, D. H., Liu, J., Hao, Y., Liu, J., et al. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01662-3 · Cited by 11
After 70 Years, Metabolic Surgery Has Earned a Cardiovascular Outcome Trial
Schauer, P. R., & Nissen, S. E. (2021) · Circulation · doi:10.1161/circulationaha.120.051752 · Cited by 11
Ali, M. K., Singh, K., Kondal, D., Devarajan, R., Patel, S. A., Menon, V. U., Varthakavi, P. K., Vishwanathan, V., Dharmalingam, M., Bantwal, G., et al. (2024) · PLOS Medicine · doi:10.1371/journal.pmed.1004335 · Cited by 10
Wahinya, M., & Khan, Z. U. (2023) · Cureus · doi:10.7759/cureus.37388 · Cited by 10
Ishigaki, Y., Hirase, T., Pathadka, S., Cai, Z., Sato, M., Takemura, R., & Ishida, N. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01484-4 · Cited by 11
Blin, P., Joubert, M., Patrick Jourdain, M., Zaoui, P., Guiard, E., Sakr, D., Dureau‐Pournin, C., Bernard, M., Lassalle, R., Thomas‐Delecourt, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02101-1 · Cited by 10
Ooi, Y., Sarvanandan, T., Hee, N. K. Y., Lim, Q., Paramasivam, S. S., Ratnasingam, J., Vethakkan, S. R., Lim, S. K., & Lim, L. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0244 · Cited by 11
Kim, J., Yoon, Y., Kim, Y., Park, J., Choi, K., Nam, J., Lee, C., Son, J., Park, J., & Kim, U. (2024) · Clinical Cardiology · doi:10.1002/clc.24248 · Cited by 10
Zhou, J. S., Wang, X., Tang, R., Kou, M., Ma, H., Li, X., Heianza, Y., Fonseca, V. A., & Qi, L. (2024) · BMC Medicine · doi:10.1186/s12916-024-03288-0 · Cited by 10
Katsuyama, H., Hakoshima, M., Heshiki, T., Iida, S., Adachi, H., & Yanai, H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111752 · Cited by 11
Zhao, M., Dong, Y., Chen, L., & Shen, H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305954 · Cited by 13
Evaluating diabetic foot care knowledge and practices at education level
Alrashed, F. A., Iqbal, M., Al-Regaiey, K., Ansari, A. A., Alderaa, A. A., Alhammad, S. A., Alsubiheen, A. M., & Ahmad, T. (2024) · Medicine · doi:10.1097/md.0000000000039449 · Cited by 10
Razaghizad, A., Ni, J., Marques, P. S., Mavrakanas, T. A., Tsoukas, M. A., Possik, E., Huynh, T. T., Edwards, J. D., Liu, P. P., Swardfager, W., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15768 · Cited by 12
Type 1 diabetes prediction in autoantibody-positive individuals: performance, time and money matter
Ferrat, L. A., Templeman, E. L., Steck, A. K., Parikh, H. M., You, L., Önengüt-Gümüşcü, S., Gottlieb, P. A., Triolo, T. M., Rich, S. S., Krischer, J. P., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06434-2 · Cited by 11
Subclinical Coronary Atherosclerosis and Retinal Optical Coherence Tomography Angiography
Yang, J. M., Yang, D. H., Lee, S.-W., Kwak, J., Lee, Y., Kim, Y. J., Lee, J., Sung, K. R., & Yoon, Y. H. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.3036 · Cited by 10
Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes
Lindholt, J. S., Frystyk, J., Hallas, J., Rasmussen, L. M., & Diederichsen, A. C. P. (2020) · Clinical Epidemiology · doi:10.2147/clep.s246636 · Cited by 10
Bernfort, L., Husberg, M., Wiréhn, A.-B., Rosenqvist, U., Gustavsson, S., Karlsdotter, K., & Levin, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00840-y · Cited by 10
Usman, M., Khunti, K., Davies, M. J., & Gillies, C. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.08.008 · Cited by 10
Asdaq, S. M. B., Lokaraja, S., Alamri, A. S., Alsanie, W. F., Alhomrani, M., Almutiri, A. H., Sreeharsha, N., & Imran, M. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9739089 · Cited by 10
Association Between Excess Sleep Duration and Risk of Stroke: A Population-Based Study
Joundi, R. A., Patten, S. B., Williams, J. V. A., & Smith, E. E. (2021) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2021.242 · Cited by 10
Zobel, E. H., von Scholten, B. J., Hansen, T. W., Persson, F., Rasmussen, S., Wolthers, B. O., & Rossing, P. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14578 · Cited by 9
Ma, T., Xie, Y. J., Bennett, T., & Lee, C. (2021) · Journal of Sports Sciences · doi:10.1080/02640414.2021.2009163 · Cited by 10
Interleukin-37: A Link Between COVID-19, Diabetes, and the Black Fungus
Tokajian, S. T., Merhi, G., Khoury, C. A., & Nemer, G. M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.788741 · Cited by 10
Brady, E. M., Gulsin, G. S., Mirkes, E. M., Parke, K. S., Kanagala, P., Ng, L. L., Graham-Brown, M. P. M., Athithan, L., Henson, J. J., Redman, E. L., et al. (2022) · Diabetic Medicine · doi:10.1111/dme.14884 · Cited by 10
Riedl, R., Robausch, M., & Berghold, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279090 · Cited by 10
Iwase, M., Ohkuma, T., Fujii, H., Oku, Y., Higashi, T., Oshiro, A., Ide, H., Nakamura, U., & Kitazono, T. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110732 · Cited by 10
Rawshani, A., Eliasson, B., Borén, J., Sattar, N. A., Bhatt, D. L., El-Khalili, L., Nordanstig, J., Avdic, T., Beckman, J. A., Gerstein, H. C., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100888 · Cited by 12
Self-citationUnexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?
Neppala, S., Rajan, J., Yang, E., & DeFronzo, R. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02055-0 · Cited by 12
Komorita, Y., Iwase, M., Idewaki, Y., Fujii, H., Ohkuma, T., Ide, H., Jodai, T., Yoshinari, M., Murao‐Kimura, A., Oku, Y., et al. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13076 · Cited by 10
Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors
Vaduganathan, M., & Januzzi, J. L. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.008 · Cited by 10
Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
SKOLNIK, N., Prato, S. D., Blonde, L., Galstyan, G. R., & Rosenstock, J. (2021) · Advances in Therapy · doi:10.1007/s12325-020-01614-5 · Cited by 10
Jiang, Y., Pang, T., Shi, R., Qian, W., Yan, W., Li, Y., & Yang, Z. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.750773 · Cited by 10
Zhang, F., Ma, Y., Yu, Y., Sun, M., Li, H., Lou, J., Cao, J., Liu, Y., Niu, M., Wang, L., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.810050 · Cited by 10
Yandrapalli, S., Malik, A. H., Horblitt, A. M., Pemmasani, G., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000311 · Cited by 9
Ferrannini, G., Bacquer, D. D., Erlund, I., Gyberg, V., Kotseva, K., Mellbin, L., Norhammar, A., Schnell, O., Tuomilehto, J. O., Vihervaara, T., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0272 · Cited by 11
Nusca, A., Piccirillo, F., Bernardini, F., Filippis, A. D., Coletti, F., Mangiacapra, F., Ricottini, E., Melfi, R., Gallo, P., Cammalleri, V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137261 · Cited by 11
Han, E., Song, S. O., Kim, H. S., Son, K. J., Jee, S. H., Soo, B., & Lee, B. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1440 · Cited by 12
Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients
Madsbad, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1615444 · Cited by 10
Li, Y., Sheu, W. H., & Lee, I. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s246032 · Cited by 10
Wan, E. Y. F., Yu, E. Y. T., Chen, J. Y., Wong, I. C. K., Chan, E. W., & Lam, C. L. K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14157 · Cited by 11
Shah, V. N., Agesen, R. M., Bardtrum, L., Christiansen, E., SNAITH, J. R., & Greenfield, J. R. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241305647 · Cited by 11
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationKe, Z., Zhou, X., Sun, F., Li, F., Tong, W., & Zhu, Z. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.11.019 · Cited by 10
Gao, Y., Shi, R., Li, Y., Guo, Y., Xu, H., Shi, K., & Yang, Z. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01785-9 · Cited by 9
Xiong, Y., Liu, Y., Hu, J., Zhu, B.-Q., Wei, Y.-K., Yang, Y. Q., Wu, X., & Long, E. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1259596 · Cited by 9
Warren, M., Bergenstal, R. M., Hager, M., Bashan, E., & Hodish, I. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0041 · Cited by 10
ELUCIDATE Trial: A Single‐Center Randomized Controlled Study
Lin, J., Liu, S.-C., Liu, T., Chuang, S., Huang, C., Chen, Y.-J., Lee, C., Chien, M.-N., Hou, C. J., Yeh, H., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033832 · Cited by 9
Uric acid and risk of incident heart failure in individuals with cardiovascular disease
Li, N., Li, Y., Cui, L., Shu, R., Li, J., Song, H., Wang, J., Chen, S., Zhu, C., Zhao, M., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.09.012 · Cited by 9
Prideaux, L., Sandeman, M., Stratton, H., Kelleher, A. D., Smith, S., & Hanson, J. (2025) · Acta Tropica · doi:10.1016/j.actatropica.2025.107559 · Cited by 9
Berger, M., Marx, N., & Marx-Schütt, K. (2025) · European Cardiology Review · doi:10.15420/ecr.2024.29 · Cited by 13
External validation of SCORE2-Diabetes risk prediction model in Chinese patients with diabetes
Fu, Z., Shen, P., Liang, J., Liu, X., Sun, Y., Chen, Q., Lin, H., Tang, X., & Gao, P. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf226 · Cited by 9
Miramontes‐González, J. P., Rodrigo-Alaíz, Á., Gabella-Martín, M., Calle, D. G., Carretero-Gómez, J., & Corral-Gudino, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01829-1 · Cited by 10
Eliasson, B., Ekelund, J., Amberntsson, R., Miftaraj, M., & Svensson, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0632-4 · Cited by 9
Self-citationMaio, R., Suraci, E., Caroleo, B., Politi, C., Gigliotti, S., Sciacqua, A., Andreozzi, F., Perticone, F., & Perticone, M. (2021) · Biomedicines · doi:10.3390/biomedicines9070721 · Cited by 9
Geldsetzer, P., Neve, J. D., Mohan, V., Prabhakaran, D., Roy, A., Tandon, N., Davies, J. I., Vollmer, S., Bärnighausen, T., & Prenissl, J. (2022) · Global Heart · doi:10.5334/gh.1056 · Cited by 10
Potential Role of SUMO and SUMOylation in the Pathogenesis of Diabetes Mellitus
Sadeghi, M., Dehnavi, S., Shohan, M., Jamialahmadi, T., Sathyapalan, T., & Sahebkar, A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220817142848 · Cited by 9
Wang, P., Li, Q., Guo, X., Zhou, Y., Li, Z., Yang, H., Yu, S., Sun, Y., & Zhang, X. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195814 · Cited by 9
Koufakis, T., Liberopoulos, E. N., Kokkinos, A. D., Zebekakis, P. E., & Kotsa, K. (2023) · Drugs · doi:10.1007/s40265-023-01852-1 · Cited by 9
Karalis, D. G. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000896 · Cited by 9
Otoda, T., Sekine, A., Uemoto, R., Tsuji, S., Hara, T., Tamaki, M., Yuasa, T., Tamaki, T., Matsuhisa, M., & Aihara, K. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01488-0 · Cited by 9
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- Uppsala University (SE)
- From the Department of Molecular and Clinical Medicine, Institute of Medicine (Aidin Rawshani, Araz Rawshani, B.E., A. Rosengren, S.G.), and the Health Metrics Unit, Sahlgrenska Academy (S.F.), University of Gothenburg, and the Swedish National Diabetes Register, Center of Registers in Region (Aidin Rawshani, Araz Rawshani, S.F., B.E., A.-M.S., M.M., S.G.), Gothenburg, and the Department of Public Health and Caring Sciences–Geriatrics, Uppsala University, and the Swedish Medical Products Agency,...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-16
- Volume
- 379
- Issue
- 7
- Pages
- 633-644
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2887185538
- Cited by
- 1,475
- References
- 22
- Citations by year
- 2026: 158 · 2025: 172 · 2024: 178 · 2023: 175 · 2022: 197 · 2021: 219 · 2020: 210 · 2019: 141 · 2018: 20
- FWCI
- 116.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular risk factors, mortality, acute myocardial infarction, stroke, heart failure hospitalization, HbA1c, LDL cholesterol, albuminuria, smoking, blood pressure, Swedish National Diabetes Register, matched cohort comparison
- MeSH terms
- Adult, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypercholesterolemia, Hypertension, Male, Middle Aged, Myocardial Infarction, Risk Factors, Smoking, Sweden, Cohort Studies, Body Mass Index, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
